Information  X 
Enter a valid email address

Astrazeneca PLC Ord (AZN)

Date Time Source Announcement
09 Sep 2021 4:00 pm
RNS
Imfinzi improves survival in NSCLC in POSEIDON
  7:00 am
RNS
PT027 PhIII asthma trials met primary endpoints
03 Sep 2021 7:00 am
RNS
Ultomiris approved in EU for children with PNH
01 Sep 2021 3:00 pm
RNS
Total Voting Rights
26 Aug 2021 7:05 am
RNS
Forxiga approved in Japan for CKD
  7:00 am
RNS
ALXN1840 Wilson Phase III met primary endpoint
20 Aug 2021 7:05 am
RNS
Update on Ultomiris Phase III ALS trial
  7:00 am
RNS
AZD7442 prophylaxis trial met primary endpoint
16 Aug 2021 3:00 pm
RNS
Director/PDMR Shareholding
11 Aug 2021 2:35 pm
RNS
Update on US review of roxadustat
09 Aug 2021 7:05 am
RNS
Forxiga approved in the EU for CKD
  7:00 am
RNS
Enhertu head-to-head trial meets primary endpoint
02 Aug 2021 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Saphnelo approved in the US for SLE
29 Jul 2021 7:00 am
RNS
AZN: H1 2021 Results
26 Jul 2021 7:00 am
RNS
Ultomiris recommended in EU for children with PNH
22 Jul 2021 7:00 am
RNS
Directorate Change
21 Jul 2021 3:56 pm
RNS
Director/PDMR Shareholding
  3:45 pm
RNS
Total Voting Rights
  1:45 pm
RNS
Acquisition of Alexion completed
19 Jul 2021 7:00 am
RNS
Imfinzi approved in China for extensive-stage SCLC
16 Jul 2021 7:00 am
RNS
Status on US FDA Advisory Committee for roxadustat
15 Jul 2021 5:30 pm
RNS
AstraZeneca
14 Jul 2021 7:08 am
RNS
AstraZeneca-Alexion transaction cleared in the UK
08 Jul 2021 7:00 am
RNS
Tezepelumab granted FDA Priority Review for asthma
06 Jul 2021 7:00 am
RNS
AstraZeneca-Alexion transaction cleared in the EU
01 Jul 2021 3:00 pm
RNS
Total Voting Rights
28 Jun 2021 7:05 am
RNS
Forxiga recommended in EU for patients with CKD
  7:00 am
RNS
Nirsevimab PhII/III trial confirms safety profile
24 Jun 2021 7:00 am
RNS
Lynparza approved in China for prostate cancer
23 Jun 2021 7:00 am
RNS
Orpathys approved in China for lung cancer
22 Jun 2021 7:00 am
RNS
Koselugo approved in the EU for children with NF1
15 Jun 2021 7:00 am
RNS
Update on AZD7442 STORM CHASER trial
10 Jun 2021 11:32 am
RNS
Stabilisation Notice
07 Jun 2021 7:00 am
RNS
Calquence head-to-head results versus ibrutinib
04 Jun 2021 7:05 am
RNS
Lynparza reduced recurrence risk in breast cancer
  7:00 am
RNS
AstraZeneca appoints new Chief Financial Officer
02 Jun 2021 7:00 am
RNS
Publication of Final Terms
01 Jun 2021 3:01 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
28 May 2021 7:00 am
RNS
Tagrisso approved in EU in early lung cancer
27 May 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
AstraZeneca prices a EUR800m bond offering
26 May 2021 9:24 am
RNS
Stabilisation Notice
  7:00 am
RNS
AstraZeneca prices a $7bn bond offering
25 May 2021 7:00 am
RNS
EMTN programme update - publication of Prospectus
21 May 2021 7:00 am
RNS
Vaxzevria COVID-19 vaccine approved in Japan
18 May 2021 3:30 pm
RNS
Director/PDMR Shareholding
11 May 2021 2:00 pm
RNS
Result of AGM
  1:55 pm
RNS
Shareholders vote in favour of Alexion acquisition
07 May 2021 7:00 am
RNS
Imfinzi + tremelimumab showed survival in POSEIDON
05 May 2021 6:30 pm
RNS
Holding(s) in Company
04 May 2021 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Farxiga approved in the US for CKD
30 Apr 2021 7:00 am
RNS
AZN: First quarter 2021 results
26 Apr 2021 7:10 am
RNS
Selumetinib recommended for EU approval in NF1

a d v e r t i s e m e n t